Loading...
Market
Which company will have a larger market share in FSHD treatments by end of 2024?
3
Resolution / Starting Odds
Avidity leads market • 33%
Fulcrum leads market • 33%
Both have similar market share • 33%
Market analysis reports and sales data
Story
Avidity Biosciences Reports Promising Phase 1/2 Data for AOC 1020 with 50% Reduction in DUX4
Jun 12, 2024, 12:26 PM
Avidity Biosciences ($RNA) announced promising results from its Phase 1/2 FORTITUDE trial for AOC 1020, targeting facioscapulohumeral muscular dystrophy (FSHD). The data showed a greater than 50 percent reduction in DUX4 regulated genes and trends of functional improvement in patients. This marks the first convincing measure of DUX4 target engagement in humans. The announcement has led to a 21.6% pre-market increase in Avidity Biosciences' stock price. Comparisons were made to Fulcrum Therapeutics' data, suggesting Avidity's drug may be more potent, though the data is at an earlier time point (16 weeks vs. 48 weeks). The results are significant for the FSHD treatment landscape, indicating potential efficacy and safety of AOC 1020. Additionally, the data derisks RWS as a more reliable endpoint for Fulcrum's upcoming readout in Q4.
View original story
Similar markets
High (>20% market share) • 33%
Moderate (10-20% market share) • 33%
Low (<10% market share) • 33%
Pfizer • 25%
Sarepta Therapeutics • 25%
Solid Biosciences • 25%
Other • 25%
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%
Viking Therapeutics • 33%
Madrigal Pharmaceuticals • 33%
GPCR • 33%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Less than $15 • 25%
$15 to $30 • 25%
$31 to $50 • 25%
More than $50 • 25%
Remains stable • 25%
Improves • 25%
Declines • 25%
Becomes market leader • 25%
North America leads adoption • 25%
Europe leads adoption • 25%
Asia leads adoption • 25%
Other regions lead adoption • 25%
Moderna leads • 33%
GSK leads • 33%
Pfizer leads • 33%